Jiangsu Hengrui Medicine Co., Ltd
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
Pharmacokinetics of HR17031 Injection in Healthy Subjects
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: HR17031 injection ；INS068 injection；SHR20004 injection
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2022-10-13
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05031871
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai, Shanghai, China
Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Kidney Function
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05032235
- Locations
- 🇨🇳
The second affiliated hospital of Chongqing medical university, Chongqing, Chongqing, China
SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05020925
- Locations
- 🇨🇳
Cancer Hospital of Guangzhou Sun Yat-sen University, Guangzhou, Guangdong, China
A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.
Phase 2
- Conditions
- IgA Nephropathy
- Interventions
- Drug: PlaceboDrug: HR19042 Capsules
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 210
- Registration Number
- NCT05016323
- Locations
- 🇨🇳
NanFang Hospital of Southern Medical University, Guangzhou, Guangdong, China
A Trial of Efficacy and Safety of Remimazolam Tosilate for Injection in Local Anesthesia Assisted Sedation
Phase 2
Completed
- Conditions
- Local Anesthesia Assisted Sedation
- Interventions
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT05015361
- Locations
- 🇨🇳
West China Hospital, Chengdu, Sichuan, China
A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy
Phase 3
Recruiting
- Conditions
- Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 1256
- Registration Number
- NCT05009290
- Locations
- 🇨🇳
Fudan University Shanghai Cancer center, Shanghai, Shanghai, China
A Phase 1 Dose Escalation and Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT04995042
- Locations
- 🇨🇳
The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics of HRS4800 in Healthy Subjects
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2021-08-31
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 96
- Registration Number
- NCT04991909
- Locations
- 🇨🇳
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Effect of Omeprazole on the Pharmacokinetics of SHR6390 in Healthy Subjects
Phase 1
Completed
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: SHR6390、Omeprazole
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04989829
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China
A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
Phase 3
Terminated
- Conditions
- Advanced Hepatocellular Carcinoma (HCC)
- Interventions
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 1
- Registration Number
- NCT04985136
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath